Using mass photometry to explore the evolution of carbon fixation
Form I Rubisco is one of the most abundant enzymes on Earth. It is responsible for assimilating atmospheric CO2 into organic matter, but how it obtained its high CO2 specificity is unknown.
Using mass photometry to study compact CRISPR-Cas12f1 complexes
Due to its precise genome editing capabilities, the prokaryotic CRISPR–Cas system has revolutionized molecular biology – and has potential applications in gene therapy and biotechnology [1]. Nonetheless, recent research has highlighted the need for more compact CRISPR-Cas complexes, which could be delivered to cellular systems more efficiently [2]
Happy 500 (papers) to mass photometry!
There is no better measure for the success of an analytical technology than its widespread adoption by the people who need the best data! As news of the capabilities and applications of mass photometry spreads, more and more scientists are choosing to use it. In fact, the number of scientific publications relying on mass photometry has grown by an average of 168% per year over the past 6 years. In August 2024, we hit a new milestone: 500 mass photometry papers! For a technology as young as mass photometry, that is truly remarkable.
Speeding up gene therapy analytics
Genetic Engineering & Biotechnology News (GEN) published a short article discussing how researchers at the UK Centre for Process Innovation (CPI) found mass photometry to be a helpful analytical technique for companies using adeno-associated viruses (AAV) as viral vectors in gene therapies.
Macro mass photometry for rapid viral vector characterization
An article authored by Laura Pala, one of our Product Marketing Managers, has recently been published by Eurolab magazine and also online at ScientistLive. It provides a useful overview of macro mass photometry and how it can help to speed up viral vector characterization, a key analytical step within the production pipeline for cell and gene therapies (CGT) and vaccines.
Expert interview on accelerating AAV development processes
ABL, an Institut Mérieux Company, is a distinguished contract development and manufacturing organization (CDMO) providing GMP viral vectors from early stage to market.
A fresh look at protein aggregation using mass photometry
Neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, both involve an accumulation of protein aggregates [1],[2]. Monitoring and studying small oligomers, which are present in the early stages of disease, can be challenging, due to their transient and heterogeneous nature [1].
Studying protein oligomerization with mass photometry
Lipoprotein lipase (LPL) has long been a focal point in the study of lipid metabolism. Its role in releasing free fatty acids from triglycerides, allowing their transport across cell membranes, is vital for energy production, while dysregulation of this enzyme has been linked to cardiovascular disease [1].
Overcome analytical bottlenecks with mass photometry
Dr. Martin E. and Dr. Marie A. are experienced scientists – characterizing antibody and gene therapy samples at one of the top 5 pharmaceutical companies. Their lab recently acquired a TwoMP Auto mass photometer and they spoke to us about their initial experience with the instrument and how they are using mass photometry to overcome their analytical challenges.
Exploring the structural dynamics of shelterin with mass photometry
Shelterin is a DNA-binding complex that facilitates telomeric DNA replication and maintenance of telomeric stability 1. Mutations in shelterin components can lead to various pathologies, including cancer predisposition and premature aging.
